An ongoing clinical trial will assess whether the adjuvant combination of the personalized cancer vaccine mRNA-4157 and pembrolizumab (Keytruda) improves recurrence-free survival (RFS) compared with pembrolizumab alone in patients with complete resection of cutaneous melanoma and a high-risk of recurrence.1
Archive | Of Interest
John Theurer Cancer Center Evaluating Personalized Cancer Vaccine in High-Risk Melanoma
Posted in Melanoma News, Health Professionals, Of Interest
Study suggests blocking immune T-cell regulator may help eliminate tumours
Immune system T-cells are more able to destroy skin cancer cells when a T-cell regulator called SLAMF6 is missing, a new study in eLife shows.
Posted in Melanoma News, Health Professionals, Of Interest
Does Methotrexate Increase Risk for Cutaneous Malignant Melanoma in Patients With Psoriasis?
Although methotrexate has been associated with an increased risk for cutaneous malignant melanoma in patients with rheumatoid arthritis, a study has found no association between methotrexate treatment and risk for this form of melanoma in patients with psoriasis.
Posted in Melanoma News, Health Professionals, Of Interest
Study examines potential link between partner bereavement and skin cancer
Psychological stress has been proposed as a risk factor for melanoma, but clinical evidence is limited. A recent British Journal of Dermatology study funded by the European Academy of Dermatology and Venereology looked for a potential link between the death of a partner, which is one of the most stressful life events, and melanoma.
Posted in Melanoma News, Health Professionals, Of Interest
